APP heparin manufacturing facility approved
Executive Summary
APP Pharmaceuticals announces Aug. 18 that FDA approved a facility in Barceloneta, Puerto Rico for the manufacture of three product codes of Heparin Sodium Injection. Currently the sole supplier of heparin in the U.S. in the wake of Baxter's heparin contamination fiasco, APP said approval of the third manufacturing facility will free up its other facilities to fulfill outstanding orders. The German health care products and services company Fresenius announced last month a $4.6 billion acquisition of APP - a buyout price that could increase if APP profits are higher than projected (1"The Pink Sheet," July 14, 2008, p. 17)
You may also be interested in...
Fresenius Fearlessly Acquires Sole Supplier Of Heparin in U.S.
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the In Vivo blog. Visit the blog at 1http://invivoblog.blogspot.com/.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.